Skip to main content
Advertisement
  • Neurology.org
  • Journals
    • Neurology
    • Clinical Practice
    • Education
    • Genetics
    • Neuroimmunology & Neuroinflammation
  • Online Sections
    • Neurology Video Journal Club
    • Diversity, Equity, & Inclusion (DEI)
    • Neurology: Clinical Practice Accelerator
    • Practice Buzz
    • Practice Current
    • Residents & Fellows
    • Without Borders
  • Collections
    • COVID-19
    • Disputes & Debates
    • Health Disparities
    • Infographics
    • Neurology Future Forecasting Series
    • Null Hypothesis
    • Patient Pages
    • Topics A-Z
    • Translations
  • Podcast
  • CME
  • About
    • About the Journals
    • Contact Us
    • Editorial Board
  • Authors
    • Submit New Manuscript
    • Submit Revised Manuscript
    • Author Center

Advanced Search

Main menu

  • Neurology.org
  • Journals
    • Neurology
    • Clinical Practice
    • Education
    • Genetics
    • Neuroimmunology & Neuroinflammation
  • Online Sections
    • Neurology Video Journal Club
    • Diversity, Equity, & Inclusion (DEI)
    • Neurology: Clinical Practice Accelerator
    • Practice Buzz
    • Practice Current
    • Residents & Fellows
    • Without Borders
  • Collections
    • COVID-19
    • Disputes & Debates
    • Health Disparities
    • Infographics
    • Neurology Future Forecasting Series
    • Null Hypothesis
    • Patient Pages
    • Topics A-Z
    • Translations
  • Podcast
  • CME
  • About
    • About the Journals
    • Contact Us
    • Editorial Board
  • Authors
    • Submit New Manuscript
    • Submit Revised Manuscript
    • Author Center
  • Home
  • Latest Articles
  • Current Issue
  • Past Issues
  • Neurology Video Journal Club
  • Residents & Fellows

User menu

  • Subscribe
  • My Alerts
  • Log in

Search

  • Advanced search
Neurology
Home
The most widely read and highly cited peer-reviewed neurology journal
  • Subscribe
  • My Alerts
  • Log in
Site Logo
  • Home
  • Latest Articles
  • Current Issue
  • Past Issues
  • Neurology Video Journal Club
  • Residents & Fellows

Share

April 14, 2020; 94 (15 Supplement) Tuesday, April 28

Medical Cannabis in the Treatment of Patients with Autism Spectrum Disorder (1648)

Jennifer McVige, Virginia Headd, Mohammed Alwahaidy, Dylan Lis, Dilpreet Kaur, Brianna Albert, Laszlo Mechtler
First published April 14, 2020,
Jennifer McVige
1Dent Neurologic Institute
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Virginia Headd
1Dent Neurologic Institute
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Mohammed Alwahaidy
1Dent Neurologic Institute
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Dylan Lis
1Dent Neurologic Institute
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Dilpreet Kaur
1Dent Neurologic Institute
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Brianna Albert
1Dent Neurologic Institute
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Laszlo Mechtler
1Dent Neurologic Institute
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Citation
Medical Cannabis in the Treatment of Patients with Autism Spectrum Disorder (1648)
Jennifer McVige, Virginia Headd, Mohammed Alwahaidy, Dylan Lis, Dilpreet Kaur, Brianna Albert, Laszlo Mechtler
Neurology Apr 2020, 94 (15 Supplement) 1648;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Permissions

Make Comment

See Comments

Downloads
0

Share

  • Article
  • Info & Disclosures
Loading

Abstract

Objective: Evaluate efficacy and safety of medical cannabis (MC) for pain and epilepsy in patients with autism spectrum disorder (ASD).

Background: MC is approved for treatment of ASD in 14 states (not NY). In NY it is approved for epilepsy and pain. Common challenges with ASD include aggression, self-injurious behavior (SIB), elopement, pain, and epilepsy. Some individuals can also have severe behavior symptoms. Most of these patients try multiple medications with concerning side effects (SE). This study reports a case series of patients with ASD treated with MC.

Design/Methods: Retrospective chart review of 20 patients with ASD (6 with epilepsy/14 with pain) on MC treatment included written evaluation by patient or caregiver. Autism/Caregiver Global Impression of Change (ACGIC) Scale measuring: 1.Quality of life (QOL) 2.Activity limitations 3.Symptoms 4.Mood. A 10-point Likert Scale measured: 1.Chronic pain change 2.Epilepsy change 3.Secondary efficacies. MC product information: dosing, route, frequency, dispensary, and cost reported.

Results:

  1. Patients with epilepsy had improvement in seizure frequency (p =0.0032) and severity (p=0.0332).

  2. Patients with pain had improvement in degree of overall pain (p<0.0001).

  3. Autism/Caregiver Global Impression of Change (ACGIC) scale revealed improvement in all areas (p<0.0001): quality of life, activity limitations, symptoms, and mood.

  4. Secondary effects: patients experienced improvement in sleep (p<0.0001), mood (p<0.0001), and aggression towards self and/or others (p<0.0001). Improvement was also seen in patient communication abilities (p=0.0001) and attention/concentration (p=0.0002).

  5. Each patient tried an average of 6.4 other medications. 50% of patients discontinued or reduced the use of other medications.

  6. 3 patients reported mild adverse SE from MC; no SE caused discontinuation of MC.

Conclusions: There is a paucity of research on the use of MC treatment with ASD. This study supports previous research for MC treatment of pain and epilepsy while exploring indications for behavioral issues and QOL improvement in ASD patients.

Disclosure: Dr. McVige has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Amgen, Avanir, Depomed, Eli Lilly & Company, Oxtellar, Promius, Supernus, and Teva Pharmaceuticals. Dr. McVige has received research support from Amgen, Avanir, Eli Lilly, Gammacore, Impax, Teva, Boston Biomedical, Delmar Pharmaceuticals, Alder Biopharmaceuticals, and Harry Dent Family Foundation. Dr. Headd has nothing to disclose. Dr. Alwahaidy has nothing to disclose. Dr. Lis has nothing to disclose. Dr. Kaur has received research support from Dent Family Foundation. Dr. Albert has nothing to disclose. Dr. Mechtler has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Alder Pharmaceuticals, Allergan, Amgen, Avanir, Biohaven, Boston Biomedical Inc., CellDex, DelMar Pharmaceuticals, electroCore, Novartis, Orbis Pharmaceuticals, Promius, Teva Pharmaceuticals, and Jushi. Dr. Mechtler has received research support from Alder Pharmaceuticals, Allergan, Amgen, Avanir, Biohaven, Boston Biomedical Inc., CellDex, DelMar Pharmaceuticals, electroCore, Novartis, Orbis Pharmaceuticals, Promius, Teva Pharmaceuticals, and Jushi.

Letters: Rapid online correspondence

No comments have been published for this article.
Comment

REQUIREMENTS

You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.

Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.

If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.

Submission specifications:

  • Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
  • Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
  • Submit only on articles published within 6 months of issue date.
  • Do not be redundant. Read any comments already posted on the article prior to submission.
  • Submitted comments are subject to editing and editor review prior to posting.

More guidelines and information on Disputes & Debates

Compose Comment

More information about text formats

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
NOTE: The first author must also be the corresponding author of the comment.
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. higgs-boson@gmail.com
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Publishing Agreement
NOTE: All authors, besides the first/corresponding author, must complete a separate Publishing Agreement Form and provide via email to the editorial office before comments can be posted.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

You May Also be Interested in

Back to top
  • Article
  • Info & Disclosures
Advertisement

Safety and Efficacy of Tenecteplase and Alteplase in Patients With Tandem Lesion Stroke: A Post Hoc Analysis of the EXTEND-IA TNK Trials

Dr. Nicole Sur and Dr. Mausaminben Hathidara

► Watch

Related Articles

  • No related articles found.

Alert Me

  • Alert me when eletters are published
Neurology: 100 (22)

Articles

  • Ahead of Print
  • Current Issue
  • Past Issues
  • Popular Articles
  • Translations

About

  • About the Journals
  • Ethics Policies
  • Editors & Editorial Board
  • Contact Us
  • Advertise

Submit

  • Author Center
  • Submit a Manuscript
  • Information for Reviewers
  • AAN Guidelines
  • Permissions

Subscribers

  • Subscribe
  • Activate a Subscription
  • Sign up for eAlerts
  • RSS Feed
Site Logo
  • Visit neurology Template on Facebook
  • Follow neurology Template on Twitter
  • Visit Neurology on YouTube
  • Neurology
  • Neurology: Clinical Practice
  • Neurology: Education
  • Neurology: Genetics
  • Neurology: Neuroimmunology & Neuroinflammation
  • AAN.com
  • AANnews
  • Continuum
  • Brain & Life
  • Neurology Today

Wolters Kluwer Logo

Neurology | Print ISSN:0028-3878
Online ISSN:1526-632X

© 2023 American Academy of Neurology

  • Privacy Policy
  • Feedback
  • Advertise